Antibody
drug conjugate is a significant class of highly potent
bio drugs envisioned as a broad therapy for treatment of cancer.
Unlike chemotherapy, antibody drug conjugate are proposed to mark and
kill only cancer cells. Antibody drug conjugates are compound
molecules that comprise antibodies linked to a biologically active
cytotoxic drug.
By
uniting the exclusive targeting capacities of mAB with anti-cancer
drugs, ADCs allow for subtle judgment between healthy and diseased
tissue. This entails that the antibody drug conjugates kill only
cancer cells and ensure that other dynamic cells are less severely
affected. This exceptional phenomenon of killing only cancer cells
increase the importance of use of ADCs, which would indirectly boost
growth of the global antibody drug conjugates market.
Download
PDF Brochure of Research Report @
https://www.coherentmarketinsights.com/insight/request-pdf/181
Commercialization
of 7-10 ADCs in the following decade, would lead to revenue to surge
to over US$ 10 billion over the forecast period of market
In
terms of marketing, three antibody drug conjugates have received
regulatory approval. The U.S. FDA approved one of the ADC in 2001
manufactured and developed by Pfizer/Wyeth, to treat acute
myelogenous leukemia. The drug was subsequently withdrawn in June
2010, leaving only two antibody drug conjugates in the market. The
two drugs marketed for ADCs are Brentuximab vedotin and Trastuzumab
emtansine, developed and manufactured by Seattle Genetics and
Millennium/Takeda and Genentech and Roche, respectively. Around 45
antibody drug conjugates molecules are under clinical trials, with
the preclinical pipeline expanding at a high rate. Of all the 45
molecules, around 25% are under Phase II or Phase III of development.
Frequently used cytotoxins for antibody drug conjugates under trials
include auristatin, calicheamicin, maytansine and duocarmycin.
Auristatin is the dominant compound accounting for over 50% of
antibody drug conjugates in clinical development. Roche has 10
compounds under clinical trials, and this is the most developed
pipeline of antibody drug conjugates. Globally, 70%-80% of antibody
drug conjugates manufacturing is currently outsourced. There are
limited number of contract manufacturers that have high-end
manufacturing equipment for development of cytotoxins.
Major
pharmaceutical company opt for contract manufacturer for development
and manufacture of antibody drug conjugates
Regional
segmentation of the antibody drug conjugates market by Coherent
Market Insights comprises North America, Europe, Asia Pacific, Latin
America, Middle East, and Africa. Europe accounts for the largest
share in the global market mainly due to presence of many contract
manufacturing companies with advanced manufacturing equipment. Lonza
is one of the top contract manufacturing companies in Europe, which
has operations across France and Germany, with its headquarters in
Switzerland. One of the facilities operated by the company is a deck
to chemical manufacturing capabilities and develop peptides, small
molecule active pharmaceutical ingredients, highly potent active
pharmaceutical ingredients, cytotoxics agents, antibody drug
conjugates, and microbial products. The company also offer
proficiency in chemical, pharmaceutical, agrochemical and food
industries by providing clients with yields such as high-class active
substances, organic chemicals and intermediates.
Request
For Customization of Research Report @
https://www.coherentmarketinsights.com/insight/request-customization/181
Large
number of clinical trial molecules in pipeline to boost growth of
antibody drug conjugates market
Key
players operating the antibody drug conjugates market include
Hoffmann-La Roche Ltd, Seattle Genetics, Takeda, ImmunoGen Inc,
Pfizer Inc., Sanofi, AbbVie Inc, Cellldex Therapeutics, Synthon, and
Progenics Pharmaceuticals. Major companies in the antibody drug
conjugates industry are constantly working on research and
development, as the market is largely untapped and offer highly
lucrative growth opportunities. For instance, there are only two
antibody drug conjugates available worldwide that are used to treat
cancer, and there are over 40 molecules under clinical trials.
Considering the alarmingly high incidence rate of cancer across the
globe, the antibody conjugates market is expected to ride on a wave
of positive growth in the foreseeable future.
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm
offering action-ready syndicated research reports, custom market
analysis, consulting services, and competitive analysis through
various recommendations related to emerging market trends,
technologies, and potential absolute dollar opportunity.
Contact
Us:
Mr.
Shah
Coherent
Market Insights
1001
4th Ave,
#3200
Seattle,
WA 98154
Tel:
+1-206-701-6702
0 comments:
Post a Comment